Upregulation of microRNA-138-5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 5135-5140

  Yu, Chao ^a   Wang, Min ^b   Chen, Meiyuan ^a   Huang, Yang ^a   Jiang, Jianxin ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

MicroRNA 138 5p; MTT; Pancreatic cancer; Vimentin; Western blotting

Indexed keywords

FLUOROURACIL; LENTIVIRUS VECTOR; MICRORNA; MICRORNA 138 5P; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIMENTIN; ANTINEOPLASTIC AGENT; MESSENGER RNA; MIRN138 MICRORNA, HUMAN;

ARTICLE; CANCER CHEMOTHERAPY; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREATIC CANCER CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; BINDING SITE; CELL MOTION; CHEMISTRY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; RNA INTERFERENCE; RNA, MESSENGER; VIMENTIN;

EID: 84940505983     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4031     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Chen W, Zheng R, Zhang S, et al: Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res 25: 10-21, 2013.
3. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
4. Hirata K, Egawa S, Kimura Y, et al: Current status of surgery for pancreatic cancer. Dig Surg 24: 137-147, 2007.
5. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H and Kleeff J: Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7: e1000267, 2010.
6. Pillai RS: MicroRNA function: Multiple mechanisms for a tiny RNA? RNA 11: 1753-1761, 2005.
7. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
8. Feng W and Feng Y: MicroRNAs in neural cell development and brain diseases. Sci China Life Sci 54: 1103-1112, 2011.
9. Bian S and Sun T: Functions of noncoding RNAs in neural development and neurological diseases. Mol Neurobiol 44: 359-373, 2011.
10. Papagiannakopoulos T and Kosik KS: MicroRNAs: Regulators of oncogenesis and stemness. BMC Med 6: 15, 2008.
11. Blandino G, Fazi F, Donzelli S, et al: Tumor suppressor microRNAs: A novel non-coding alliance against cancer. FEBS Lett 588: 2639-2652, 2014.
12. Palanichamy JK and Rao DS: miRNA dysregulation in cancer: Towards a mechanistic understanding. Front Genet 5: 54, 2014.
13. Wang Y, Kim S and Kim IM: Regulation of metastasis by microRNAs in ovarian cancer. Front Oncol 4: 143, 2014.
14. Othman N and Nagoor NH: The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatment. Biomed Res Int 2014: 318030, 2014.
15. Han C, Yu Z, Duan Z and Kan Q: Role of microRNA-1 in human cancer and its therapeutic potentials. Biomed Res Int 2014: 428371, 2014.
16. Gao Y, Fan X, Li W, Ping W, Deng Y and Fu X: miR-138-5p reverses geftinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochem Biophys Res Commun 446: 179-186, 2014.
17. Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT: MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 33: 1113-1120, 2012.
18. Zhao X, Yang L, Hu J and Ruan J: miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 34: 1078-1082, 2010.
19. Radulovich N, Qian JY and Tsao MS: Human pancreatic duct epithelial cell model for KRAS transformation. Methods Enzymol 439: 1-13, 2008.
20. Zhang L, Mizumoto K, Sato N, et al: Quantitative determination of apoptotic death in cultured human pancreatic cancer cells by propidium iodide and digitonin. Cancer Lett 142: 129-137, 1999.
21. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S and Singh G: Overexpression of vimentin: Role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 63: 2306-2311, 2003.
22. Wang L, Gu F, Liu CY, Wang RJ, Li J and Xu JY: High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol 34: 853-858, 2013.
23. Li ZM, Wen YJ, Yang HB, et al: Enhanced expression of human vimentin intermediate filaments in hepatocellular carcinoma cells decreases their proliferative and invasive abilities in vitro. Zhonghua Zhong Liu Za Zhi 30: 408-412, 2008 (In Chinese).
24. Gilles C, Polette M, Mestdagt M, et al: Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 63: 2658-2664, 2003.
25. Korsching E, Packeisen J, Liedtke C, et al: The origin of vimentin expression in invasive breast cancer: Epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Oathol 206: 451-457, 2005.